Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.044
- Book/Share 16.3757
- PB 1.5434
- Debt/Equity 0.665
- CurrentRatio 1.2822
- ROIC 0.1065
- MktCap 143251401773.0
- FreeCF/Share 1.8252
- PFCF 13.806
- PE 14.5844
- Debt/Assets 0.2957
- DivYield 0.0683
- ROE 0.1091
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | PFE | Citigroup | -- | Neutral | -- | $26 | Dec. 2, 2025 |
| Initiation | PFE | Scotiabank | -- | Sector Outperform | -- | $30 | Nov. 13, 2025 |
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.
Read More
Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound
Published: December 19, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worrying execution risks tied to COVID franchise headwinds, loss of exclusivity, and the need for robust pipeline execution in oncology and obesity. Management's focus is on advancing multiple Phase III studies and commercializing new assets, but near-term valuation upside is unlikely until clearer growth visibility emerges.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Pfizer Stock Can Sink More. Here Is How
Published: December 17, 2025 by: Forbes
Sentiment: Negative
Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.
Read More
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Negative
PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.
Read More
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Published: December 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Read More
Pfizer shares fall after it forecasts 2026 revenue below estimates
Published: December 16, 2025 by: Proactive Investors
Sentiment: Negative
Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of COVID-19 products fall and generic competition rises. The company forecast revenue between $59.5 billion and $62.5 billion for 2026, with adjusted earnings per share of $2.80 to $3.
Read More
Pfizer's modest 2026 outlook shows its big investments will take time to pay off
Published: December 16, 2025 by: CNBC
Sentiment: Negative
Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit of $2.80 to $3 per share next year, and revenue of $59.5 billion to $62.5 billion.
Read More
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Pfizer Declares First-Quarter 2026 Dividend
Published: December 12, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to brin.
Read More
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports
Published: December 10, 2025 by: Reuters
Sentiment: Negative
Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.
Read More
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill
Published: December 09, 2025 by: CNBC
Sentiment: Positive
Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space. YaoPharma's oral drug works by targeting the same gut hormone, GLP-1, as Novo Nordisk's blockbuster weight loss injection Wegovy, but the pill is still in early-stage development.
Read More
Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons
Published: December 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
In the rushed emergency use approval of Covid vaccines, deaths were undisclosed. Thousands received shots before warnings of heart damage were released.
Read More
Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains
Published: December 09, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds. PFE maintains strong free cash flow and improved guidance, targeting $61–$64 billion in 2025 revenue and $3–$3.15 adjusted EPS, while managing leverage post-acquisitions. Patent expirations threaten $17–$18 billion in annual revenue by 2026–2028, but aggressive acquisitions, R&D investments and cost savings aim to offset losses and drive long-term growth.
Read More
Pfizer: The Market Is Still Wrong About It
Published: December 05, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer's stock rebounded from April lows yet still trades as if COVID and patent cliffs equal business ruin, despite resilient non‑COVID franchises and pipeline optionality. Q3 looked weak, with revenue and EPS down year-over-year, yet both beat estimates as Vyndaqel, Nurtec, and Padcev collectively offset fading COVID contributions. Pfizer's adjusted margin stayed near seventy‑six percent, and OPEX fell, while a $1.5 billion manufacturing optimization program should expand margins and earnings by 2027.
Read More
Pfizer (PFE) Up 3.9% Since Last Earnings Report: Can It Continue?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Read More
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
Read More
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Read More
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
Published: December 01, 2025 by: Investopedia
Sentiment: Neutral
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Read More
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Published: December 01, 2025 by: Market Watch
Sentiment: Negative
Memo also reportedly mentions vaccines for flu and pneumonia.
Read More
8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills
Published: November 28, 2025 by: Seeking Alpha
Sentiment: Positive
Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project net gains of 18.44% to 29.95% for the top ten BBB Dogs by November 2026, with an average estimated gain of 22.01%. Stocks are considered 'dogs' when their reliable dividends and lower prices result in higher yields; eight of the top ten are already at ideal pricing levels.
Read More
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.
Read More
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.
Read More
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
Published: November 21, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy.
Read More
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
Read More
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Positive
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees "more opportunity for alpha than beta" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners.
Read More
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Published: November 14, 2025 by: CNBC Television
Sentiment: Positive
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Read More
Pfizer CEO: AI will help with medicine's next big breakthrough
Published: November 13, 2025 by: Yahoo Finance
Sentiment: Positive
Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical giant is bright. The company plans to enter the GLP-1 space by 2028 and aims to become a leader in the obesity market.
Read More
Pfizer Completes Acquisition of Metsera
Published: November 13, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. “This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth ther.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000